Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results...

|By:, SA News Editor

Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results from its Phase 3 clinical trail of cabozantinib in patients with medullary thyroid cancer. The company aims to build a cabozantinib franchise that includes large indications such as prostate cancer.